MedTrace Logo

Efficacy and Safety of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients

NCT00410930 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2006-12-19

No results posted yet for this study

Summary

To compare versus placebo the efficacy and safety of recombinant Bet v1, natural purified Bet v1 and birch pollen licenced extract used for subcutaneous immunotherapy.

Conditions

  • Allergy

Interventions

BIOLOGICAL

Subcutaneous immunotherapy - Recombinant birch pollen

Sponsors & Collaborators

  • Stallergenes Greer

    lead INDUSTRY

Principal Investigators

  • Gabrielle PAULI, MD, Pr · Hôpital Liautey - Strasbourg, France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-11-30
Completion
2005-11-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00410930 on ClinicalTrials.gov